CBT logo

Cabot (CBT)

Profile

Full Name

Cabot Corporation

Ticker Symbol

CBT

Exchange

NYSE

Sector

Basic Materials

Industry

Specialty Chemicals

Country

United States

IPO

November 5, 1980

Indexes

Not included

Website

http://www.cabotcorp.com

Employees

4151

Key Details

Price

$79.11(-0.45%)

Market cap

$4.29B(Mid cap)

Last Dividend

$0.43

TTM Dividend yield

2.17%

Annual revenue

$3.99B(+1.60% YoY)

Annual EPS

$6.72(-13.07% YoY)

PE ratio

10.51

Next earnings date

May 5, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$79.11
CBT price is $79.11

30-Day Relative Volume

0.89
CBT 30-day relative volume is 0.89

Price Performance

Price Most recent change

-0.45%
CBT price was down -0.45% on Apr 14, 2025

Price YTD change

-13.36%
CBT price is down -13.36% since January 1st

Price 1-year change

-15.18%
CBT price is down -15.18% year-on-year

Price 3-year change

+17.88%
CBT price is up +17.88% over the past 3 years

Price Range

Price All-time high

$117.46
CBT price is currently -32.65% below its historical high of $117.46

Price 3-year low

$59.65
CBT price is currently +32.62% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$4.29B
CBT market capitalization is $4.29 billion

Market cap 3-year change

+13.26%
CBT market capitalization is up +13.26% over the past 3 years

Market cap All-time high

$6.47B
CBT market capitalization is currently -33.74% below its historical high of $6.47 billion

Market cap sector rank

75.28%
CBT market capitalization is higher than 75.28% of companies in Basic Materials sector

Shares Outstanding

Shares Outstanding 1-Year Change

-1.88%
CBT shares outstanding is down -1.88% year-on-year

Shares Outstanding 3-Year Change

-3.92%
CBT shares outstanding is down -3.92% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.89
CBT beta is 0.89

200-day SMA

$97.03
CBT price is currently -18.47% below its 200-day simple moving average

50-day SMA

$83.73
CBT price is currently -5.52% below its 50-day simple moving average

RSI

44.49
CBT 14-day relative strength index is 44.49

Volume

0.89
CBT 30-day relative volume is 0.89

ATR

$3.65
CBT average true range is $3.65

10-day Historical Volatility

61.52%
CBT 10-day historical volatility is 61.52%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$0.43
CBT last dividend was $0.43 per share, with an ex-dividend date of February 28, 2025

Next Dividend

-
CBT next dividend has not yet been announced

Dividend per share

Dividend per share

$1.66
CBT annual dividend per share is $1.66

Dividend per share Sector Rank

72.87%
CBT annual dividend per share is higher than 72.87% of companies in Basic Materials sector

Dividend per share 1-Year Change

+7.79%
CBT annual dividend per share is up +7.79% year-on-year

Dividend per share 3-Year Change

+18.57%
CBT annual dividend per share is up +18.57% over the past 3 years

Dividend yield

Dividend yield

2.10%
CBT annual dividend yield is 2.10%

Dividend yield Sector Rank

50%
CBT annual dividend yield is higher than 50% of companies in Basic Materials sector

Other

Payout ratio

24.47%
CBT annual payout ratio is 24.47%

Dividends paid

$93.00M
CBT annual dividends paid is $93.00 million

Free cash flow

$451.00M
CBT annual free cash flow is $451.00 million

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$3.99B
CBT annual revenue is $3.99 billion

Revenue Analysts estimate

$4.08B
CBT annual revenue is currently -2.21% lower than the consensus analysts' forecast

Revenue 1-year change

+1.6%
CBT annual revenue is up +1.6% year-on-year

Revenue Sector rank

72.69%
CBT annual revenue is higher than 72.69% of companies in Basic Materials sector

EPS

EPS

$6.72
CBT annual earnings per share is $6.72

EPS Analysts estimate

$7.53
CBT annual earnings per share is currently -10.77% lower than the consensus analysts' forecast

EPS 1-year change

-13.07%
CBT annual earnings per share is down -13.07% year-on-year

EPS Sector rank

92.16%
CBT annual earnings per share is higher than 92.16% of companies in Basic Materials sector

Profit

Gross profit

$960.00M
CBT annual gross profit is $960.00 million

Gross margin

24.04%
CBT annual gross profit margin is 24.04%

Operating profit

$614.00M
CBT annual operating income is $614.00 million

Operating margin

15.37%
CBT annual operating profit margin is 15.37%

Net income

$380.00M
CBT annual net profit is $380.00 million

Net margin

9.51%
CBT annual net profit margin is 9.51%

Expenses

Total expenses

$3.38B
CBT annual total expenses is $3.38 billion

Operating expenses

$346.00M
CBT annual total operating expenses is $346.00 million

Cost of goods sold

$3.03B
CBT annual cost of goods sold is $3.03 billion

Selling, general & administrative expenses

$283.00M
CBT annual SGA is $283.00 million

Depreciation and amortization

$151.00M
CBT annual depreciation & amortization is $151.00 million

Interest expense

$81.00M
CBT annual interest expense is $81.00 million

Income tax

$111.00M
CBT annual income tax is $111.00 million

EBIT & EBITDA

EBIT

$610.00M
CBT annual earnings before interest & taxes is $610.00 million

EBITDA

$761.00M
CBT annual EBITDA is $761.00 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$3.74B
CBT annual total assets is $3.74 billion

Non current assets

$2.13B
CBT annual long term assets is $2.13 billion

Current assets

$1.60B
CBT annual total current assets is $1.60 billion

Cash and cash equivalents

$223.00M
CBT annual cash & cash equivalents is $223.00 million

Accounts receivable

$733.00M
CBT annual accounts receivable is $733.00 million

Inventory

$552.00M
CBT annual inventory is $552.00 million

Liabilities

Total liabilities

$2.15B
CBT annual total liabilities is $2.15 billion

Long term liabilities

$1.37B
CBT annual total long term liabilities is $1.37 billion

Current liabilities

$772.00M
CBT annual total current liabilities is $772.00 million

Accounts payable

$495.00M
CBT annual accounts payable is $495.00 million

Debt

Total debt

$1.14B
CBT annual total debt is $1.14 billion

Total debt 1-year change

-16.18%
CBT annual total debt is down -16.18% year-on-year

Long term debt

$1.09B
CBT annual long term debt is $1.09 billion

Short term debt

$53.00M
CBT annual short term debt is $53.00 million

Equity & Capital

Shareholders equity

$1.43B
CBT annual stockholders equity is $1.43 billion

Book value

$1.43B
CBT annual book value is $1.43 billion

Retained earnings

$1.73B
CBT annual retained earnings is $1.73 billion

Working capital

$833.00M
CBT annual working capital is $833.00 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$692.00M
CBT annual cash flow from operations is $692.00 million

Cash from operations 1-year change

+16.3%
CBT annual cash flow from operations is up +16.3% year-on-year

Cash from investing

-$235.00M
CBT annual cash flow from investing activities is -$235.00 million

Cash from investing 1-year change

-9.81%
CBT annual cash flow from investing activities is down -9.81% year-on-year

Cash from financing

-$415.00M
CBT annual cash flow from financing activities is -$415.00 million

Cash from financing 1-year change

-2.98%
CBT annual cash flow from financing activities is down -2.98% year-on-year

CAPEX

CAPEX

$241.00M
CBT annual capital expenditures is $241.00 million

CAPEX 1-year change

-1.23%
CBT annual capital expenditures is down -1.23% year-on-year

Free Cash Flow

Free cash flow

$451.00M
CBT annual free cash flow is $451.00 million

Free cash flow 1-year change

+28.49%
CBT annual free cash flow is up +28.49% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

24.04%
CBT annual gross profit margin is 24.04%

Operating margin

15.37%
CBT annual operating profit margin is 15.37%

Net margin

9.51%
CBT annual net profit margin is 9.51%

ROA & ROE

ROA

10.35%
CBT annual return on assets is 10.35%

ROE

25.36%
CBT annual return on equity is 25.36%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

10.51
CBT price to earnings ratio is 10.51

PE ratio Sector rank

18.9%
CBT price to earnings ratio is higher than 18.9% of companies in Basic Materials sector

PB Ratio

PB ratio

3.14
CBT price to book ratio is 3.14

PB ratio Sector rank

78.2%
CBT price to book ratio is higher than 78.2% of companies in Basic Materials sector

PS Ratio

PS ratio

1.07
CBT price to sales ratio is 1.07

PS ratio Sector rank

45.05%
CBT price to sales ratio is higher than 45.05% of companies in Basic Materials sector

Enterprise value

Enterprise value

$5.30B
CBT enterprise value is $5.30 billion

Enterprise value Sector rank

73.76%
CBT enterprise value is higher than 73.76% of companies in Basic Materials sector

EV/EBITDA

EV/EBITDA

6.61
CBT EV/EBITDA is 6.61

EV/EBITDA Sector rank

52.89%
CBT EV/EBITDA is higher than 52.89% of companies in Basic Materials sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.08
CBT annual current ratio is 2.08

Quick ratio

1.36
CBT annual quick ratio is 1.36

Leverage

Debt to equity

0.80
CBT annual debt to equity ratio is 0.80

Interest coverage ratio

7.53
CBT annual interest coverage ratio is 7.53

Risk & Stability

Piotroski F-Score

7
CBT piotroski f-score is 7

Altman Z-Score

3.72
CBT altman z-score is 3.72

Analyst ratings

Recent major analysts updates

Apr 7, 25 UBS
Neutral
Feb 21, 25 JP Morgan
Underweight
Jan 7, 25 Mizuho
Outperform
Nov 11, 24 JP Morgan
Underweight
Nov 5, 24 Mizuho
Outperform
Aug 7, 24 JP Morgan
Neutral
Aug 6, 24 UBS
Neutral
May 7, 24 UBS
Neutral
May 7, 24 Mizuho
Buy
Apr 18, 24 Deutsche Bank
Hold

Institutional Ownership

Similar stocks

CE logo
Celanese (CE)
TFPM logo
Triple Flag Precious Metals (TFPM)
OR logo
Osisko Gold Royalties Ltd (OR)
IAG logo
IAMGOLD (IAG)
BTG logo
B2Gold (BTG)
MP logo
MP Materials (MP)
ESI logo
Element Solutions (ESI)
EGO logo
Eldorado Gold (EGO)
FMC logo
FMC (FMC)
  • What is the ticker symbol for Cabot?
  • Does Cabot pay dividends?
  • What sector is Cabot in?
  • What industry is Cabot in?
  • What country is Cabot based in?
  • When did Cabot go public?
  • Is Cabot in the S&P 500?
  • Is Cabot in the NASDAQ 100?
  • Is Cabot in the Dow Jones?
  • When was Cabot's last earnings report?
  • When does Cabot report earnings?
  • Should I buy Cabot stock now?

What is the ticker symbol for Cabot?

The ticker symbol for Cabot is NYSE:CBT

Does Cabot pay dividends?

Yes, Cabot pays dividends. The last payment was $0.43, with an ex-dividend date on February 28, 2025

What sector is Cabot in?

Cabot is in the Basic Materials sector

What industry is Cabot in?

Cabot is in the Specialty Chemicals industry

What country is Cabot based in?

Cabot is headquartered in United States

When did Cabot go public?

Cabot's initial public offering (IPO) was on November 5, 1980

Is Cabot in the S&P 500?

No, Cabot is not included in the S&P 500 index

Is Cabot in the NASDAQ 100?

No, Cabot is not included in the NASDAQ 100 index

Is Cabot in the Dow Jones?

No, Cabot is not included in the Dow Jones index

When was Cabot's last earnings report?

Cabot's most recent earnings report was on Feb 3, 2025

When does Cabot report earnings?

The next expected earnings date for Cabot is May 5, 2025

Should I buy Cabot stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page